deltatrials
Completed PHASE4 INTERVENTIONAL 1-arm NCT00171886

Octreotide Efficacy and Safety in First-line Acromegalic Patients

Sponsor: Novartis Pharmaceuticals

Conditions Acromegaly
Interventions Octreotide
Updated 7 times since 2017 Last updated: Feb 23, 2017 Started: Jul 31, 2002 Primary completion: May 31, 2006 Completion: May 31, 2006
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Acromegaly, this trial is completed. The trial is conducted by Novartis Pharmaceuticals and has accumulated 7 data snapshots since 2002. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Mar 2017 · 59 days · monthly snapshotSuspended~Mar 2017 – ~Jun 2018 · 15 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 10 months · monthly snapshotCompleted

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE4

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE4

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE4

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE4

▶ Show 2 earlier versions

  1. Mar 2017 — Jun 2018 [monthly]

    Completed PHASE4

    Status: Suspended → Completed

  2. Jan 2017 — Mar 2017 [monthly]

    Suspended PHASE4

    First recorded

Jul 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novartis Pharmaceuticals
Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations